StockNews.com Upgrades Prestige Consumer Healthcare (NYSE:PBH) to Buy

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Several other analysts have also issued reports on the stock. Canaccord Genuity Group increased their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th. Finally, Oppenheimer increased their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average target price of $92.60.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH opened at $84.87 on Tuesday. The company’s 50 day moving average price is $81.67 and its two-hundred day moving average price is $78.38. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $90.04. The firm has a market cap of $4.20 billion, a PE ratio of 19.88, a PEG ratio of 2.69 and a beta of 0.46. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities research analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC raised its stake in shares of Prestige Consumer Healthcare by 14.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company’s stock valued at $649,000 after acquiring an additional 1,030 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $7,778,000. Kayne Anderson Rudnick Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $84,932,000. Vise Technologies Inc. bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $319,000. Finally, McIlrath & Eck LLC raised its stake in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after acquiring an additional 154 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.